News Feed Item

Delivra Reports Record Q3 Revenues and Licensing Agreement for the Transdermal Delivery of Medical Cannabis During the Quarter

TORONTO, ON--(Marketwired - November 30, 2016) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") reported its financial results for the three and nine month periods ended September 30, 2016. All figures are reported in CDN dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Q3 2016 Highlights:

  • Solidified the Company's position as having the #1 Selling Natural Pain Cream in Canada and the #1 Selling Nerve Pain Cream in Canada (adapted from Nielson data, April 2016);
  • Completed a licensing agreement with Canopy Growth Corporation (TSX: CGC) for the transdermal delivery of medical cannabis;
  • Q3-2016 generated revenues of $630,265, a 42% increase over Q3-2015. Pain and nerve sales are seasonal and historically the slowest during the third quarter of each year;
  • Filed four permanent patents during the quarter, bringing the total number of patents pending to six and the total number of permanent patent filings to four;
  • Secured an additional $495,000 of government funding relating to the U.S. market entry in the form of unsecured, interest-free loans;
  • Received proceeds on interest-free government loans in the amount of $280,397, and after quarter end, an additional $653,518. Proceeds received were used for scientific research on certain transdermal products and U.S. market entry expenditures;
  • Raised $2,020,900 through the issuance of convertible debentures on a non-brokered private placement;
  • R&D development of the transdermal delivery potential of the very popular pain management drug, celecoxib;
  • Starting in June and throughout Q3-2016, investment made in building brand awareness in the U.S.; and
  • Subsequent to quarter end, the Company announced its successful pre-clinical work with the natural ingredient berberine for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels.

"Our strategy of improving the safety and efficacy of existing drugs using Delivra's proprietary transdermal delivery technology platform continues to drive a portfolio of robust pharmaceutical and natural products in our pipeline. During the quarter, we successfully grew our LivRelief suite of products in Canada, while leveraging the value of our delivery system platform, including diabetes and innovative cannabis-based products. The completion of a licensing agreement with Canopy Growth Corporation, our second licensing agreement for the transdermal delivery of medical cannabis, addresses the growing demand for topical cannabis as a therapeutic option for a range of conditions. Through this collaboration, Delivra will offer consumers a unique product suite. We are excited at the opportunity of licensing these natural and Rx products globally," said Dr. Joseph Gabriele, CEO of Delivra Corp.

Results of Operations


Revenue for Q3-2016 was $630,265, a 42% increase compared to Q3-2015 of $444,866. Revenues for the first nine months of 2016 were $2,734,768, an increase of 32% compared to the same period in 2015 of $2,071,270. The main drivers of this growth for the first nine months of 2016 were:

  1. 34% increase in adjusted unit sales over the comparative period of the Company's pain products in Canada, including repeat purchases and new customer acquisitions resulting from the Company's on-going marketing and advertising efforts, and
  2. 54% increase in unit sales over the comparative period of the Company's Nerve Pain product in Canada.

This increase in nerve product sales is a result of a planned reallocation of marketing and advertising expenditures beginning in Q2-2016. The nerve product advertising represented an investment by the Company in the latent growth potential of the product, which the Company believes is underrepresented in the overall revenue mix by comparison to the flagship Pain product. While this may result in lower revenue in the short-term, versus the same advertising spending allocation to Pain product, it strengthens the brand, solidifies the leadership position of Nerve, diversifies the customer base, and provides a broader platform for continued forward growth.

Gross Profit

Gross Profit for Q3-2016 was $406,919, a 45% increase compared to Q3-2015 of $280,032. This is a result of increased revenues and efficiencies in the production process during the year (65% in Q3-2016 versus 63% in Q3-2015). Gross Profit for the first nine months of 2016 was up 36% against the comparable prior period, at $1,864,363 versus $1,374,785 in the first nine months of 2015. Gross margin was 68% in the first nine months of 2016 versus 66% in the first nine months of 2015.

Operating Expenses

Operating expenses for Q3-2016 were $2,334,223, up from $1,026,681 in Q3-2015. Operating expenses for the first nine months of 2016 were $5,596,783, versus $2,803,483 in the first nine months of 2015. The increase was mainly a result of higher marketing and selling costs associated with successful growth and brand building investments in Canada and initial US test marketing costs. In Canada, in the first nine months of 2016, the Company spent approximately $200,000 more in television advertising, which generated an additional $489,578 in gross margins, compared to the prior period. Sales and marketing salaries increased approximately $110,000 during the year, as a result of diversification and growth initiatives into professional channels (eg. medical and clinical). Lastly, the Company spent approximately $2,125,000 on aggressive US brand building initiatives during the nine-month period. Although the Company will continue with these efforts, it will be on a less aggressive basis in Q4 2016 and 2017, as the Company continues to refine and develop strategies for the US market based on the knowledge gained from these efforts.

Net Loss

The net loss and comprehensive loss for Q3-2016 was $2,246,347 or $0.06 per share versus $772,541 or $0.02 per share for Q3-2015. The net loss and comprehensive loss for the first nine months of 2016 was $4,241,331 or $0.11 per share versus $1,494,435 in the first nine months of 2015 or 0.05. The increased loss occurred from the results of operations discussed above, primarily the investments made in core growth, US expansion, share-based compensation and public company G&A costs. In addition, the loss for the three and nine months includes $266,596 relating to the accretion expense on convertible debentures and fair value change in derivatives related to the convertible debentures.


Delivra Corp. ("Delivra" or the "Company") is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the transdermal delivery of repurposing Rx molecules to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com for Canada and www.livrelief.com/us for the United States.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
SYS-CON Events announced today that Datanami has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datanami is a communication channel dedicated to providing insight, analysis and up-to-the-minute information about emerging trends and solutions in Big Data. The publication sheds light on all cutting-edge technologies including networking, storage and applications, and the...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
SYS-CON Events announced today that EnterpriseTech has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. EnterpriseTech is a professional resource for news and intelligence covering the migration of high-end technologies into the enterprise and business-IT industry, with a special focus on high-tech solutions in new product development, workload management, increased effi...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, paneli...
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex software systems for startups and enterprises. Since 2009 it has grown from a small group of passionate engineers and business...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
SYS-CON Events announced today that Ayehu will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara California. Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infras...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...